Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma

Eleftherios Spartalis; Dimitrios I Athanasiadis; Dimosthenis Chrysikos; Michael Spartalis; Georgios Boutzios; Dimitrios Schizas; Nikolaos Garmpis; Christos Damaskos; Stavroula A Paschou; Argyrios Ioannidis; Gerasimos Tsourouflis; Dimitrios Dimitroulis; Nikolaos I Nikiteas

doi:10.21873/anticanres.13220

Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma

Anticancer Res. 2019 Mar;39(3):1119-1127. doi: 10.21873/anticanres.13220.

Authors

Affiliations

¹ Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, National and Kapodistrian University of Athens, Athens, Greece eleftherios.spartalis@gmail.com.
² 1st Department of Surgery, "Papageorgiou" General Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ University Department of Surgery, General and Oncologic Hospital of Kifissia 'Agii Anargiri', Athens, Greece.
⁴ Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
⁵ Endocrine Unit, Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
⁶ 1st Department of Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
⁷ 2nd Department of Propaedeutic Surgery, Medical School, National and Kapodistrian University of Athens Athens, Greece.

PMID: 30842140
DOI: 10.21873/anticanres.13220

Abstract

Background/aim: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, remaining generally incurable. Histone deacetylase (HDAC) seems to play a role in regulating transcription of genes involved in ATC, making HDAC inhibitors (HDACI) promising anticancer drugs for ATC. The purpose of this review was to evaluate the role of HDACIs in ATC treatment and describe the latest trends of current research on this field.

Materials and methods: This literature review was performed using the MEDLINE database. The keywords/phrases were; thyroid cancer, anaplastic, HDAC, histone, deacetylase*, HDACI.

Results: Compounds, such as SuberoylAnilide Hydroxamic Acid, valproic acid, sodium butyrate, butyrate, phenylbutyrate, trichostatin A, AB1-13, panobinostat or LBH589, belinostat, MS-275, depsipeptide, CUDC101, CUDC907, N-Hydroxy-7-(2-naphthylthio)-Hepanomide (HNHA), and PXD101 have shown promising antitumor effects against ATC.

Conclusion: HDACIs represent a promising therapy for ATC management, both as monotherapy and in combination with other anticancer drugs.

Keywords: HDAC; anaplastic; cancer; histone deacetylase inhibitors; review; thyroid.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Histone Deacetylase Inhibitors / therapeutic use*
Humans
Thyroid Carcinoma, Anaplastic / drug therapy*
Thyroid Neoplasms / drug therapy*

Substances

Antineoplastic Agents
Histone Deacetylase Inhibitors